Deregulated crosstalk within nuclear receptor/transcription factor family, comprising of peroxisome proliferator-activated receptors (PPARs) and liver X receptor-a (LXR-a), can give rise to cooperativity between lipid peroxidation and inflammation leading to atherogenic process. The present study addressed to explore the effect of statins and vitamin 'C' on transcriptional expression of genes coding for this nuclear receptor/transcription factor family within mononuclear cells revealed for the first time that both mevastatin and vitamin 'C' have common action in that they significantly downregulate the expression of PPARs (a, g) genes and upregulate LXR-a gene expression as compared to the control. The similar phenomenon was observed in mononuclear cells obtained from coronary heart disease (CHD) patients who were receiving atorvastatin treatment (20 mg HS). Further, the observed upregulatory effect of LXR-a gene expression was in conformity with the downregulatory effect of LXR-a on its effector gene matrix metalloproteinase-9. Based on these results, we propose that LXR-a-dependent signaling pathway may be a crucial target for the therapeutic intervention in human CHD, and in addition to statins, vitamin 'C' deserves a close scrutiny for the treatment of CHD.
Cooperativity between lipid peroxidation and inflammation has been widely recognized to initiate a complex interaction between blood mononuclear cells (neutrophils, lymphocytes and monocytes) and cells within vascular wall leading to atherogenic process (Kutuk & Basaga, 2003) . The first stage at which these two pathological processes intersect seems to be the regulation of nuclear receptor/transcription factor family involving peroxisome proliferator-activated receptors (PPARs a, g) and liver X receptor-a (LXR-a) in a manner that gives rise to the development of early lesions. This receptor/transcription factor family is activated by end-products of lipid peroxidation and regulate expression of multiple genes involved in lipid metabolism, uptake, efflux, cell-adhesion molecules and proinflammatory cytokines (Kaul, 2003) . Further pleiotropic effects of statins on macrophage growth, adhesion molecules, proinflammatory cytokines, LDL-oxidation and platelet aggregation have contributed to their clinical benefits in the treatment of coronary heart disease (CHD) (Lechleitner, 2002) . On the other hand, vitamin 'C' has also been shown to reduce lipid oxidation (Hillstrom et al, 2003) , NF-kB activity (Carcamo et al, 2002) , adhesion molecules, platelet aggregation (Loshak, 2002) and increase HDL level (Salonen et al, 2003) , which makes this vitamin useful for prevention/ treatment of CHD (Levine et al, 1996) . Keeping all the above-mentioned facts in view, the present study was addressed to explore the effect of statins and vitamin 'C' on transcriptional expression of genes coding for nuclear receptors PPARs (a, g) and LXR-a within human mononuclear cells. Venous blood samples were collected from 10 normal human subjects (normal control), 10 hyperlipidemic CHD patients (who were on atorvastatin therapy-20 mg HS for a period of at least 6 months) and 10 untreated hyperlipidemic subjects without CHD (disease control), who had been fasting for 12 h before blood donation. The subjects were males aged between 37 and 62 y of age. The criteria for CHD were: myocardial infarction (chest pain associated with electrocardiographic (ECG) evidence of myocardial infarction or raised cardiac enzymes or both); unstable angina (cardiac pain associated with dynamic ECG abnormalities); and angiographically proven coronary artery disease (450% stenosis in one or more major epicardial vessel in multiple projections). The exclusion criteria for both patients and controls included cardiomyopathy, serious organ disease, systemic illness, chronic alcohol abuse, serious psychiatric illness, anticonvulsant therapy and, for controls, the presence of pathological Q waves on the ECG. The study was approved by our institute research ethics committee and all individuals gave written, informed consent.
The mononuclear cells were obtained by employing Ficoll-Hypaque density-gradient method (Boyum, 1968) . The viability of cells was determined by Trypan blue exclusion test using 0.4% Trypan blue These cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% FCS; 2 mM L-glutamine; 20 mM sodium bicarbonate; 20 mM HEPES; 50 U/ml benzylpenicillin and 50 mg/ml streptomycin at 371C in a humidified 5% CO 2 incubator. The cells were seeded at 2 Â 10 5 cells/well and subsequently exposed to growth medium enriched with either no stimulus or mevastatin (30 mM) or vitamin 'C' (0.0-0.2 mg/ml) for 24 h at 371C in 5% CO 2 atmosphere. At the end of the incubation period, these cells together with mononuclear cells [obtained from normal human subjects (normal control), untreated hyperlipidemic subjects without CHD (disease control), hyperlipidemic CHD patients who were on atorvastatin therapy-20 mg HS for a period of at least 6 months and untreated hyperlipidemic subjects without CHD exposed to vitamin 'C' (0.2 mg/ml) in vitro culture, respectively] were processed for RNA isolation (Chomczynski & Sacchi, 1987) . The integrity of isolated RNA was verified by electrophoresis through denaturing agarose gels stained with ethidium bromide. First-strand cDNA was synthesized using random hexamer primers and Moloney murine leukemia virus reverse transcriptase in 20 ml reaction volume. Reagents were obtained from RevertAid TM first strand cDNA synthesis kit (Fermentas). cDNA of each sample was amplified by PCR using specific primers for genes coding for PPARs (a,g), LXR-a, matrix metalloproteinase-9 (MMP-9) and b 2 microglobulin (b 2 M) (Marx et al, 1998; Girando et al, 2004; Kaul et al, 2004) . b 2 M amplification was used as a control for RNA loading and efficiency of reverse transcription. PCR reagents were procured from Qiagen and MBI Fermentas. The specific primers were obtained from GENSET Singapore Biotech Pvt Ltd and MWG-Biotech AG. PCR was performed in a 25 ml reaction mixture containing 1 Â PCR buffer, 2.5 mM MgCl 2 , 0.2 mM of each dNTP, 0.5 mM of each primer and 0.625 U of Taq (Thermus aquaticus) and nuclease-free water. A measure of 1 ml of cDNA from cDNA synthesis reaction mixture was used as a template in each PCR. The PCR cycling conditions of these genes were selected such that they were in the linear phase of amplification. Table 1 indicates the number of amplification cycles and the sequence of the primers used. The amplicons were resolved in 2% agarose gels containing ethidium bromide. The ethidium bromide-stained products were photographed and the intensity of bands was analyzed using Scion Image analysis software. The level of mRNA expression of each gene was given by normalizing RT-PCR band intensity of the gene in question to b 2 M band intensity. The exposure of cells to mevastatin resulted in significant reduction in the expression of genes coding for PPAR-a and PPAR-g coupled with about 3.5-fold increase in LXR-a gene expression as compared to the control (see Figure 1a) . Vitamin 'C' treatment exhibited dose-dependent reduction in the transcriptional expression of PPARs (a, g) that was accompanied by dose-dependent increase in LXR-a gene expression (see Figure 1b) . Further cells derived from atorvastatin-treated CHD patients exhibited decreased expression of genes coding for PPARs (a, g) accompanied by significant increase in LXR-a gene transcription (see Figure 2) . These results provide incontrovertible evidence to support the view that both statins (in vitro and in vivo) and vitamin 'C' have identical effect on the expression of genes coding for PPARs (a, g) and LXR-a. Keeping in view the fact that gene coding for MMP-9 is specifically downregulated by LXR-a protein at the transcriptional level (Centrillo et al, 2003) , we explored whether or not both statins and vitamin 'C' have the ability to downregulate MMP-9 gene transcription through their observed upregulatory effect on LXR-a gene transcription. The results of such a study reported in Figure 3 unambiguously reveal that MMP-9 mRNA expression is downregulated by atorvastatin-and vitamin 'C'-treated cells as compared to the disease control (untreated hyperlipidemic subjects without CHD). Understanding the crosstalk between lipid peroxidation and inflammation requires identification of the molecular mechanism responsible for the inter-relationship between PPARs (a, g), LXR-a and their effector genes. Consequently, the signaling pathways generated by this nuclear receptor/transcription factor family that regulate monocyte transmigration into subendothelial space appears to be the point of intersection between lipid peroxidation and inflammation, and have the inherent capacity to be a potential therapeutic target. It is in this Genomic effect of vitamin 'C' and statins D Kaul and MI Baba context the results reported here assume importance. It is interesting to note that statins and vitamin 'C' share a common pathway in that they both downregulate PPARs (a, g) transcription coupled with significant upregulation of LXR-a gene (see Figures 1 and 2 ) and significant downregulation of its effector gene (MMP-9) (see Figure 3 ). This result raises certain basic questions, especially whether or not clinical efficacy of statins against CHD is mediated through their ability to regulate LXR-a gene expression? Although the data presented here are not sufficient here to answer this question, it is pertinent to note various observations: (a) LXR-a has been shown to decrease inflammation by downregulating genes coding for iNOS, IL-1b, IL-6, COX2 and MMP-9, and increased cholesterol efflux by upregulating genes coding for ABCA1, ApoE/CII and PLTP . (b) Synthetic LXR-a ligands inhibit atherosclerosis in animals . Hence, these observations point to the fact that LXRa-dependent signaling pathway may be a crucial target for the therapeutic intervention in human CHD. The inherent capacity of vitamin 'C' ability to activate selectively LXR-adependent signaling pathway may be of crucial importance in prevention/treatment of CHD, especially keeping in view the fact that observed effect of vitamin 'C' lies well within the permissible dose of this vitamin. Further vitamin 'C' may also be useful in suppressing the vicious cycle created by cooperativity between lipid peroxidation and inflammation, which is the crucial trigger in the development of early atherosclerotic lesion. However, further studies are required before this view becomes acceptable. (ii) hyperlipidemic subjects with CHD receiving atorvastatin treatment (20 mg HS); and (iii) untreated hyperlipidemic subjects without CHD exposed to vitamin 'C' (0.2 mg/ml) in vitro culture. Results are expressed as RT-PCR product relative abundance in hyperlipidemic subjects with CHD receiving atorvastatin treatment and untreated hyperlipidemic subjects without CHD exposed to vitamin 'C' in vitro culture as compared to disease controls ( ¼ 100). For each gene, levels of mRNA were measured as the ratio of signal intensity to b 2 M. Values are mean7s.e.m. and were significantly different from control at *Po0.001. Each experiment was carried out in triplicate.
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